(B) The chances percentage of treatment-related adverse occasions leading to loss of life calculated from the arbitrary effect (RE) magic size in Group B (PD-1/PD-L1 + Chemotherapy Chemotherapy)

(B) The chances percentage of treatment-related adverse occasions leading to loss of life calculated from the arbitrary effect (RE) magic size in Group B (PD-1/PD-L1 + Chemotherapy Chemotherapy). Supplementary Shape 2: Funnel plots for group A (PD-1/PD-L1 vs Chemotherapy) (A) The chances percentage of treatment-related undesirable events resulting in death calculated from the set impact (FE) model (PD-1/PD-L1 vs Chemotherapy). Subgroup evaluation was performed predicated on PD-1/PD-L1. (B) The chances percentage of treatment-related adverse occasions resulting in discontinuation calculated from the set impact (FE) model (PD-1/PD-L1 vs Chemotherapy). Subgroup evaluation was completed predicated on PD-1/PD-L1. (C) The chances percentage of all-grade treatment-related adverse occasions calculated from the set impact (FE) model (PD-1/PD-L1 vs Chemotherapy). Subgroup evaluation was conducted predicated on PD-1/PD-L1. (D) The chances ratio of quality 3-5 treatment-related adverse occasions calculated by set impact (FE) model (PD-1/PD-L1 vs Chemotherapy). Subgroup evaluation was performed predicated on PD-1/PD-L1. Picture_2.tif (1.4M) GUID:?09763096-76E5-4C32-992D-A00BD3D9514F Supplementary Shape 3: Funnel plots of treatment-related adverse events resulting in loss Domatinostat tosylate of life (A) The funnel storyline of treatment-related adverse events resulting in death calculated from the set effect (FE) magic size in Group A (PD-1/PD-L1 vs Chemotherapy). Subgroup evaluation was performed predicated on tumor types. (B) The funnel storyline of treatment-related adverse occasions leading to loss of life calculated from the set impact (FE) model in Group B (PD-1/PD-L1+Chemotherapy vs Chemotherapy). Subgroup evaluation was performed predicated on tumor types. (C) The funnel storyline of treatment-related adverse occasions leading to loss of life calculated from the set impact (FE) model in Group C (PD-1/PD-L1 vs Placebo). (D) The funnel storyline of treatment-related adverse occasions leading to loss of life calculated from the set impact (FE) model in Group D (PD-1 vs PD-1+CTLA-4). Subgroup evaluation was performed predicated on tumor types. (E) The funnel storyline of treatment-related adverse occasions leading to loss of life calculated from the set impact (FE) model in Group E (PD-1+CTLA-4 vs CTLA-4). (F) The funnel storyline of treatment-related adverse occasions leading to loss of life calculated from the set impact (FE) model in Group F (PD-1 vs CTLA-4). (G) The funnel storyline of treatment-related adverse occasions leading to loss Domatinostat tosylate of life calculated from the set impact (FE) model in Group G (PD-1/PD-L1 vs PD-1/PD-L1+Chemotherapy). Picture_3.tif (2.4M) GUID:?DC59D554-BBB4-4DA0-B3BC-C11E266F2C11 Supplementary Shape 4: Funnel plots of the chance of treatment-related adverse events resulting in discontinuation (A) The funnel Domatinostat tosylate storyline of treatment-related adverse events resulting in discontinuation calculated from the set effect (FE) magic size in Group A (PD-1/PD-L1 vs Chemotherapy). Subgroup evaluation was performed predicated on tumor types, PD-1/PD-L1 and treatment regimens. (B) The funnel storyline of treatment-related adverse occasions leading to loss of life calculated from the set impact (FE) model in Group B (PD-1/PD-L1+Chemotherapy vs Chemotherapy). Subgroup evaluation was performed predicated on PD-1/PD-L1. (C) The funnel storyline of treatment-related adverse occasions resulting in discontinuation calculated from the set impact (FE) model in Group C CXADR (PD-1/PD-L1 vs Placebo). Subgroup evaluation was performed predicated on tumor types. (D) The funnel storyline of treatment-related adverse occasions resulting in discontinuation calculated from the set impact (FE) model in Group D (PD-1 vs PD-1+CTLA-4). Subgroup evaluation was performed predicated on tumor types. (E) The funnel storyline of treatment-related adverse occasions resulting in discontinuation calculated from the set impact (FE) model in Group E (PD-1+CTLA-4 vs CTLA-4). (F) The funnel storyline of treatment-related adverse occasions resulting in discontinuation calculated from the set impact (FE) model in Group F (PD-1 vs CTLA-4). Picture_4.tif (2.0M) GUID:?C4604C64-794E-4B16-9D7D-A40013F23115 Supplementary Figure 5: Funnel plots of all-grade treatment-related adverse events (A) The funnel plot of all-grade treatment-related adverse events calculated from the fixed effect (FE) model in Group A (PD-1/PD-L1 vs Chemotherapy) Subgroup analysis was performed predicated on tumor types, PD-1/PD-L1 and treatment regimens. (B) The funnel storyline of all-grade treatment-related adverse occasions calculated from the set impact (FE) model in Group B (PD-1/PD-L1+Chemotherapy vs Chemotherapy). Subgroup evaluation was performed predicated on tumor and PD-1/PD-L1 types. (C) The funnel storyline for all quality treatment-related adverse occasions calculated from the set impact (FE) model in Group C (PD-1/PD-L1 vs Placebo). Subgroup evaluation was performed predicated on PD-1/PD-L1 and tumor types. (D) The funnel storyline of all-grade treatment-related adverse occasions calculated from the set impact (FE) model in Group D (PD-1 vs PD-1+CTLA-4). Subgroup evaluation was performed predicated on tumor types. (E) The funnel storyline of all-grade treatment-related adverse occasions calculated.